CPR Provides Fast, Affordable Repairs for Phones, Tablets, Laptops and Game Consoles

INDEPENDENCE, OH / ACCESSWIRE / April 25, 2019 / The largest mobile repair franchise continues its expansion across the United States with the addition of a new store in New York. CPR Cell Phone Repair welcomes store owner, Eric Cronin, to the network and congratulates him on opening his first franchise location, CPR Syosset.

To learn more about CPR Cell Phone Repair Syosset, please visit: https://www.cellphonerepair.com/syosset-ny/.

“CPR is very pleased to be associated with one of the first smartphone repair centers in the Syosset area,” said Josh Sevick, CEO of CPR Cell Phone Repair. “Eric brings a great deal of experience to the table, and we’re looking forward to seeing his store succeed.”

Eric’s store is located on the North Shore of Long Island, approximately 30 miles east of Manhattan. CPR Syosset sits conveniently off the Jericho Turnpike, surrounded by a plethora of restaurants, retail centers, and other businesses. After noticing a lack of smartphone-centric repair centers in his area, Eric decided it was time to open his own shop. He and his team focus on delivering affordable and convenient solutions for a variety of device-related issues, including water damage, faulty batteries, and cracked screens. CPR Syosset services cell phones, tablets, laptops and computers, gaming consoles, and more.

“As a lifelong Long Island resident, I knew there was a need for better device repair options,” said Eric. “My goal is to help our community members find the solutions they’re looking for through quality service.”

Eric grew up in Massapequa, New York, but he currently lives in Bellmore. In his spare time away from managing his store, he enjoys weight lifting, graphic design, and traveling. Mobile repair has also been a big part of his life, as he has restored cell phones for nearly two decades. To begin a repair at CPR Syosset or to request a free estimate on any service, visit the store at the details below.

CPR Cell Phone Repair Syosset is located at:

601 Jericho Turnpike

Syosset, NY 11791

Please contact the store at 516-364-0002 or via email: repairs@cpr-syosset.com

Please visit the website: https://www.cellphonerepair.com/syosset-ny/.

About CPR Cell Phone Repair:

Founded in Orlando, Fla. in 1996, CPR Cell Phone Repair is the fastest growing wireless technology franchise in North America and operates over 550 locations internationally. As a pioneer and leader in the electronics repair industry, CPR offers same-day repair and refurbishing services for cell phones, laptops, gaming systems, digital music players, tablets, and other personal electronic devices. For four straight years, CPR was named in Entrepreneur Magazine’s Franchise 500 List. In 2019, CPR was ranked in the top 25 of the list and placed as the number one business for tech business franchises. For more information about CPR Cell Phone Repair and franchise opportunities, visit https://www.cellphonerepair.com/ or call 877-856-5101.

Contact:

Jeff Gasner

jeff@cellphonerepair.com

877-856-5101

SOURCE: CPR Cell Phone Repair

ReleaseID: 543006

4AutoInsuranceQuote Recently Posted a New Article that Takes an In-Depth Look at the Best Roadside Assistance Companies and Programs

NEW YORK, NY / ACCESSWIRE / April 25, 2019 / The founders of 4AutoInsuranceQuote, an auto insurance quote comparison engine based in New York City, are pleased to announce that they have just posted a new article that reviews many of the roadside assistance programs and companies.

To read the new article, which is titled “What Are the Best Roadside Assistance Programs and Companies?” in its entirety, please check out https://www.4autoinsurancequote.com/blog/best-roadside-assistance-companies/.

As a company spokesperson noted, in addition to striving to save drivers money on their car insurance, the founders of 4AutoInsuranceQuote are also determined to help people find the best programs and services that are related to owning a vehicle. This inspired them to spend hours researching the new article, and taking a thorough look at 10 roadside assistance programs.

After compiling the research and taking an in-depth look at the 10 companies, the founders of 4AutoInsuranceQuote have determined that AAA is the best roadside assistance program that is currently available.

“The American Automobile Association, or AAA, is one of the best-known roadside assistance programs in the country,” the article notes, adding that AAA was founded in 1902 and now has 58 million members across the United States and Canada.

“The company offers roadside assistance, automotive repair, travel assistance, and other services to members. AAA’s Classic plan is priced at just $66 per year, with a Premier plan starting at $127.”

Whether a driver is locked out of his or her vehicle, is dealing with a dead battery or requires a long tow, a AAA roadside assistance subscription can quickly pay for itself, the article notes.

Other roadside assistance companies and programs that received high marks from 4AutoInsuranceQuote include Allstate Motor Club, which is priced at $7 to $12 per month for the first year. Drivers do not have to be an Allstate insurance company customer to sign up for this program, and the Motor Club provides 24/7 roadside assistance for services like towing and tire changes.

Good Sam Roadside Assistance, National Motor Club and Paragon Motor Club were also reviewed in the article, along with several other companies.

About 4AutoInsuranceQuote:

4AutoInsuranceQuote is a car insurance quote comparison engine based in New York City. In business since 2008, 4AutoInsuranceQuote has helped millions of Americans save money on their monthly insurance bill. Please visit https://www.4autoinsurancequote.com today for a free quote to see how much 4AutoInsuranceQuote can help drivers save.

Contact:

John Smith
webmaster@4autoinsurancequote.com
4015807272

SOURCE: 4AutoInsuranceQuote

ReleaseID: 543005

SURREY, BC / ACCESSWIRE / April 25, 2019 / Larry W. Reaugh, President and Chief Executive Officer of American Manganese Inc. (“American Manganese” or “AMY” or the “Company”), is pleased to announce that the Company will be holding its annual general meeting of shareholders on May 24, 2019 at 11:00am. The meeting will be hosted at 777 Hornby Street, Suite 950, Vancouver, BC. All shareholders are invited to attend.

About American Manganese Inc.

American Manganese Inc. is a critical metals company focused on the recycling of lithium-ion batteries with the RecycLiCoTM Patented Process. The process provides high extraction of cathode metals, such as lithium, cobalt, nickel, manganese, and aluminum at battery grade purity, with minimal processing steps. American Manganese Inc. aims to commercialize its breakthrough RecycLiCoTM Patented Process and become an industry leader in recycling cathode materials from spent lithium-ion batteries.

On behalf of Management

AMERICAN MANGANESE INC.

Larry W. Reaugh
President and Chief Executive Officer
Telephone: 778 574 4444
Email: lreaugh@amymn.com

www.americanmanganeseinc.com
www.recyclico.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain “forward-looking statements”, which are statements about the future based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. Forward–looking statements by their nature involve risks and uncertainties, and there can be no assurance that such statements will prove to be accurate or true. Investors should not place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by law.

SOURCE: American Manganese Inc.

ReleaseID: 542979

SAN MATEO, CA / ACCESSWIRE / April 25, 2019 / Allysta Pharmaceuticals, Inc. (Allysta) today announced that Henry Hsu, M.D., the company’s Chief Executive Officer and President, will present at OIS@ASCRS on May 2, 2019, in San Diego, California. Dr. Hsu will present an overview of the development program for its novel, first-in-class peptide therapeutic in a morning breakout session focused on new drugs being developed for dry eye disease.

About OIS

The Ophthalmology Innovation Summits (OIS) facilitate meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs. OIS@ASCRS unites over 500 industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs.

About Allysta Pharmaceuticals, Inc.

Allysta is a privately-held biopharmaceutical company developing first-in-class peptide therapeutics with a focus in dry eye and liver diseases. The company’s lead compound, ALY688, acts as an agonist of the adiponectin receptor and induces adiponectin-like responses. Since its discovery more than 20 years ago as a major hormone produced by adipocytes and other cell types, many studies have shown that adiponectin has beneficial actions on multiple organs and cell types because of its anti-inflammatory, insulin-sensitizing, anti-atherogenic, anti-steatotic, and anti-fibrotic properties. This broad range of activity provides an opportunity to evaluate ALY688 in multiple disease indications. Data from disease models have been consistent with predicted biologic effects. For example, in ocular models of dry eye and corneal injury, ALY688 decreased inflammation on the ocular surface (both T cell and pro-inflammatory cytokines) and promoted rapid healing (re-epithelization) following corneal injury. Additionally, in models of liver fibrosis, ALY688 reduced inflammation, hepatocyte injury, and fibrosis.

Company Contact:

Info@Allysta.com
www.allysta.com

Allysta Media Contact:

Cris Larson, CFO
Allysta Pharmaceuticals
clarson@allysta.com

SOURCE: Allysta Pharmaceuticals, Inc.

ReleaseID: 542525

MORRISVILLE, NC / ACCESSWIRE / April 25, 2019 / Issuer Direct Corporation (NYSE American: ISDR), an industry-leading communications and compliance company, today announced it will host a conference call and live webcast on Thursday May 2, 2019 at 4:30 PM Eastern Time to discuss the results of the first quarter ended March 31, 2019.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: May 2, 2019
Time: 4:30 PM ET
Participant: 877.407.8133 | 201.689.8040

Live Webcast is also available via Investor Network https://www.investornetwork.com/event/presentation/47580

Conference Call Replay Information

The replay will be available beginning approximately 1 hour after the completion of the live event at https://www.issuerdirect.com/company/earnings-calls-transcripts

Reply Toll-free: 877.481.4010
International: 919.882.2331
Reference ID: 47580

About Issuer Direct Corporation

Issuer Direct® is an industry-leading communications and compliance company focusing on the needs of corporate issuers. Issuer Direct’s principal platform, Platform id., empowers users by thoughtfully integrating the most relevant tools, technologies, and services, thus eliminating the complexity associated with producing and distributing financial and business communications. Headquartered in RTP, NC, Issuer Direct serves more than 4,000 public and private companies in more than 18 countries on an annual basis. For more information, please visit www.issuerdirect.com.

Forward-Looking Statements

This press release contains ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the ”Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words ”believe,” ”anticipate,” ”estimate,” ”expect,” ”intend,” ”plan,” ”project,” ”prospects,” ”outlook,” and similar words or expressions, or future or conditional verbs such as ”will,” ”should,” ”would,” ”may,” and ”could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to and undertakes no obligation to revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2017, including but not limited to the discussion under ”Risk Factors” therein, which the Company with the SEC and which may be viewed at http://www.sec.gov/.

For Further Information:

Issuer Direct Corporation
Brian R. Balbirnie
919-481-4000
brian.balbirnie@issuerdirect.com

Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Issuer Direct Corporation

ReleaseID: 542622

CALGARY, AB / ACCESSWIRE / April 25, 2019 / CEMATRIX Corporation (OTCQB: CTXXF; TSX-V: CVX) (the “Corporation” or “CEMATRIX”) will present at the Planet MicroCap Showcase on Wednesday, May 1, 2019 and will conduct 1 on 1 meetings on May 2, 2019.

The conference will be held April 30 – May 2, 2019 at Bally’s Hotel & Casino in Las Vegas, NV – 3645 S Las Vegas Blvd., Las Vegas, NV 89109. For those interested in attending and meeting with management, you can register to attend here: https://planetmicrocapshowcase.com/signup.

If you have any questions about the Planet MicroCap Showcase, please contact Robert Kraft at rkraft@snnwire.com (424) 227-9018, or visit www.planetmicrocapshowcase.com for more information.

About Planet MicroCap Showcase

Planet MicroCap Showcase brings together promising companies with well-known and influential microcap investors, fund managers and newsletter writers for three days of company presentations, one-on-one meetings, and networking in the nation’s #1 destination for meetings and entertainment.

If you would like to attend the Planet MicroCap Showcase, please register here: https://planetmicrocapshowcase.com/signup.

CEMATRIX is an Alberta corporation with its head offices in Calgary, Alberta. The Corporation, through its wholly owned subsidiaries, is a rapidly growing company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations. This unique cement-based material with superior thermal protection, delivers a cost-effective, innovative solution to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Jeff Kendrick – President and Chief Executive Officer
Phone: (403) 219-0484
Jeff Walker, The Howard Group – Investor Relations
Phone: (888) 221-0915 or (403) 221-0915
jeff@howardgroupinc.com

Forward-looking information: This news release contains certain information that is forward looking and is subject to important risks and uncertainties (such statements are usually accompanied by words such as “anticipate”, expect”, “would’ or other similar words). Forward looking statements in this document are intended to provide CEMATRIX security holders and potential investors with information regarding CEMATRIX and its subsidiaries’ future financial and operations plans and outlook. All forward looking statements reflect CEMATRIX’s beliefs and assumptions based on information available at the time the statements were made. Readers are cautioned not to place undue reliance on this forward looking information. CEMATRIX undertakes no obligation to update or revise forward looking information except as required by law. For additional information on the assumptions made and the risks and uncertainties which may cause actual results to differ from the anticipated results, refer the CEMATRIX’s Management Discussion and Analysis dated April 2nd, 2019 under CEMATRIX’s profile on SEDAR at www.sedar.com and other reports filed by CEMATRIX with Canadian securities regulators.

News Compliments of ACCESSWIRE.

SOURCE: CEMATRIX Corporation

ReleaseID: 542952

VANCOUVER, BC / ACCESSWIRE / April 25, 2018 / GGX GOLD CORP. (TSX.V: GGX) (OTCQB: GGXXF) (the “Company” or “GGX”) announces the appointment of George Sookochoff as President of GGX Gold. George has over 35 years of experience in the junior mining sector providing consulting services in the area of project development, data analysis and management and digital marketing. He holds a Commerce Degree (Marketing-Computer Sciences) from the University of British Columbia.

He has served as a director for several junior mining companies and as past President and CEO of International PBX Ventures Ltd., a TSX venture company developing several copper porphyry and gold skarn projects in Chile. George also served as Executive Vice President of Golden Dawn Minerals where one of his duties was data acquisition and analysis of exploration data in the Greenwood mining camp.

George was born and raised in Grand Forks and is quite familiar with the region and its rich mining history along with the importance that mining has played for the families of Grand Forks, Greenwood and area over the last one hundred years.

George commented “Throughout my long career in the junior mining sector and having worked on numerous exploration projects around the world it has always been my strong belief that the Greenwood mining camp, with its rich history in mining, still remains to be the one of the best exploration areas in the world.

I am both excited and honored to return to the Greenwood camp as President of GGX Gold Corp and to further advance and develop the very significant high grade COD vein system along with the numerous other vein systems on the Gold Drop property.

I invite all GGX shareholders as well as all prospective investors to join me in our exciting journey as we continue to develop the full potential of the rich Gold Drop property.”

Barry Brown current President and CEO will remain as CEO and has been appointed Chairman of the Board.

The Company also announces it has granted 500,000 options at an exercise price of $0.10. The options are exercisable for five years and will be cancelled 30 days after cessation of acting as director, officer, employee or consultant of the Company.

On Behalf of the Board of Directors
Barry Brown, CEO
604-488-3900
office@GGXgold.com

Investor Relations:

Mr. Jack Singh, 604-488-3900, ir@GGXgold.com
“We don’t have to do this,
we get to do this”
~The Crew

Forward Looking Statement

This News Release may contain forward-looking statements including but not limited to comments regarding the acquisition of certain mineral claims. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements and Revolver undertakes no obligation to update such statements, except as required by law.

Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates, including that: the current price of and demand for minerals being targeted by the Company will be sustained or will improve; the Company will be able to obtain required exploration licences and other permits; general business and economic conditions will not change in a material adverse manner; financing will be available if and when needed on reasonable terms; the Company will not experience any material accident; and the Company will be able to identify and acquire additional mineral interests on reasonable terms or at all. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including: that resource exploration and development is a speculative business; that environmental laws and regulations may become more onerous; that the Company may not be able to raise additional funds when necessary; fluctuations in currency exchange rates; fluctuating prices of commodities; operating hazards and risks; competition; potential inability to find suitable acquisition opportunities and/or complete the same; and other risks and uncertainties listed in the Company’s public filings. These risks, as well as others, could cause actual results and events to vary significantly. Accordingly, readers should not place undue reliance on forward-looking statements and information, which are qualified in their entirety by this cautionary statement. There can be no assurance that forward-looking information, or the material factors or assumptions used to develop such forward looking information, will prove to be accurate. The Company does not undertake any obligations to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

SOURCE: GGX Gold Corp

ReleaseID: 542981

FREEHOLD, NJ / ACCESSWIRE / April 25, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has entered into a purchase agreement with several institutional investors for the purchase of 1,714,288 units in a registered direct offering, for expected gross proceeds of approximately $6 million before placement agent fees and other offering expenses payable by the Company. Each unit is being sold at a public offering price of $3.50 and consists of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $3.50. The warrants will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on April 29, 2019, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering to fund its core technology platform development and clinical studies in exosome-based liquid biopsy and regenerative therapeutics, next-generation multi-targeted CAR-T immunotherapy, co-development projects with MIT and Weill Cornell, as well as for working capital and other general corporate purposes.

Roth Capital Partners served as sole placement agent for the transaction. Maxim Group, LLC served as financial advisor to the Company.

The shares described above are being offered by the Company pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may also be obtained from Roth Capital Partners, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics (”liquid biopsy”), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Forward-Looking Statements

Certain statements contained in this press release may constitute ”forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com

SOURCE: Avalon GloboCare Corp.

ReleaseID: 543009